-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile-
-Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week 12 and 75.1% at week 8 in the 3 mg/kg dose group (reflects one dose; ongoing)-
-Complete response (UAS7=0) of 57.1% in 1.5 mg/kg dose group at week 12 and 44.4% at 8 weeks in 3 mg/kg dose group (reflects one dose; ongoing)-
-42% of patients treated with barzolvolimab had prior omalizumab and had similar symptom improvement as overall population-
-Company to host webcast conference call on Thursday, June 30 at 6:30 p.m. ET-
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
